Lorcaserin Side Effects

• headache
• Upper respiratory tract infection
• nasopharyngitis
• sinusitis
• nausea
• dizziness

Warnings & Recalls for Lorcaserin

• Because the soon-to-be-new obesity drug Lorcaserin has not been released, there is much that is yet to be discovered about the drug's adverse effects and precautions that should be taken by patients and their physicians.
• By a 9-5 vote on September 1, 2012 Lorcaserin was denied approval by a federal advisory committee. The committee was concerned about Lorcaserin's safety as well as increased tumor growth on rates that were used in Lorcaserin's pre-human testing.
• In October of 2010 Lorcaserin did not meet approval standards by the FDA due to questions of the its efficacy.

Lorcaserin Treatment and Use

Lorcaserin is poised to be the first new weight loss drug marketed in the United States in nearly 13 years. In May of 2012, FDA advisers in an 18-4 vote decided that Arena Pharmaceutical’s Lorcaserin weight loss drug which will be sold under the name Lorquess, had benefits that outweighed health risks.

The FDA panel that convened on May 10, 2012 recommended the much anticipated weight loss drug Lorcaserin with the restrictions that patients being treated with the drug must have a BMI of 30 and above or a BMI of 27 and above with obesity related conditions such as hypertension or type 2 diabetes.

How does Lorcaserin work?

The obesity drug Lorcaserin is what is known as a selective 5-HT2c receptor agonist. What this means is that Lorcaserin activates certain receptors in the brain that then activate the chemical proopiomelanocortin (POMC) which promotes a feeling of fullness. This is believed to be what  will ultimately cause weight loss due to the lower overall caloric intake.

Other Names for Lorcaserin

• Lorquess

• Lorcaserin

Lawsuits & Legal Information for Lorcaserin